Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ProSomnus, Inc. - Common Stock (NQ: OSA ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about ProSomnus, Inc. - Common Stock < Previous 1 2 Next > ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results March 26, 2024 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call March 15, 2024 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea February 22, 2024 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024 February 20, 2024 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA January 30, 2024 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices January 29, 2024 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea January 08, 2024 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices December 19, 2023 Additional clinical research indicates patients using ProSomnus devices have decreased apnea-hypopnea index events per hour, with strong treatment adherence From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results November 09, 2023 Record quarterly revenue of $7.1 million represents an increase of 41.5% year-over-year and seventh consecutive quarter of sequential revenue growth From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Announces Third Quarter 2023 Investor Call and Business Update October 31, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference October 03, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations September 21, 2023 Company will leverage new capital inflow to optimize core business operations, advance strategic growth initiatives, and achieve cash flow breakeven From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences September 14, 2023 Scientific Abstracts and Presentations Feature New and Additional Data Demonstrating the Efficacy, Effectiveness, and Safety of ProSomnus Precision Devices for the Treatment of Obstructive Sleep Apnea From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea August 23, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results August 03, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation July 13, 2023 Preliminary severe Obstructive Sleep Apnea data from FLOSAT study indicates opportunity for head-to-head trial between precision oral appliance therapy and hypoglossal nerve stimulation From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Announces Second Quarter 2023 Investor Call and Business Update July 06, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire 71% of Self-identified Snorers Have Never Consulted a Healthcare Professional June 28, 2023 National survey identifies major obstacles to treating snoring and sleep issues From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea June 08, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea May 30, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Reports First Quarter 2023 Financial Results May 09, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences April 26, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances April 24, 2023 Study data indicates that ProSomnus precision oral appliances appear to be more efficacious than traditional oral appliances for the treatment of mild, moderate, and severe Obstructive Sleep Apnea From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting April 18, 2023 Study results to be presented in oral and poster presentations at 2023 American Academy of Dental Sleep Medicine Annual Meeting From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices April 05, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results March 30, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices March 21, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 March 16, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference March 10, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire ProSomnus to Present at Two Upcoming Investor Conferences in March 2023 March 01, 2023 From ProSomnus Sleep Technologies, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.